Victor Pantea
Chisinau, CU, Republic of Moldova
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
Journal: The New England journal of medicine
Published: June 06, 2024
Rapid monophasic HBsAg decline during nucleic-acid polymer-based therapy predicts functional cure.
Journal: Hepatology communications
Published: March 23, 2023
HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
Journal: Hepatology communications
Published: December 16, 2021
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Journal: Hepatology communications
Published: January 08, 2021
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy.
Journal: Journal of viral hepatitis
Published: January 08, 2021
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
Journal: Hepatology communications
Published: September 04, 2020
Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.
Journal: Scientific reports
Published: February 04, 2020
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Journal: Gastroenterology
Published: August 01, 2019
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: July 17, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026